An eprinomectin extended-release injection formulation providing nematode control in cattle for up to 150 days

A series of 10 dose confirmation studies was conducted to evaluate the persistent activity of an extended-release injectable (ERI) formulation of eprinomectin against single point challenge infections of gastrointestinal and pulmonary nematodes of cattle. The formulation, selected based on the optimal combination of high nematode efficacy, appropriate plasma profile, and satisfactory tissue residue levels, includes 5% poly(d,l-lactide-co-glycolic)acid (PLGA) and is designed to deliver eprinomectin at a dose of 1.0 mg/kg bodyweight. Individual studies, included 16–30 cattle blocked based on pre-treatment bodyweight and randomly allocated to treatment with either ERI vehicle or saline (control), or the selected Eprinomectin ERI formulation. Treatments were administered once at a dose volume of 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder. In each study, cattle were challenged with a combination of infective stages of gastrointestinal and/or pulmonary nematodes 100, 120 or 150 days after treatment and were processed for parasite recovery according to standard techniques 25–30 days after challenge. Based on parasite counts, Eprinomectin ERI (1 mg eprinomectin/kg bodyweight) provided >90% efficacy (p < 0.05) against challenge with Cooperia oncophora and Cooperia surnabada at 100 days after treatment; against challenge with Ostertagia ostertagi, Ostertagia lyrata, Ostertagia leptospicularis, Ostertagia circumcincta, Ostertagia trifurcata, Trichostrongylus axei, and Cooperia punctata at 120 days after treatment; and against challenge with Haemonchus contortus, Bunostomum phlebotomum, Oesophagostomum radiatum and Dictyocaulus viviparus at 150 days after treatment. Results of a study to evaluate eprinomectin plasma levels in cattle treated with the Eprinomectin ERI formulation reveal a characteristic second plasma concentration peak and a profile commensurate with the duration of efficacy. These results confirm that the Eprinomectin ERI formulation can provide high levels of parasite control against a range of nematodes of cattle for up to 5 months following a single treatment.     

Nematode burdens of pastured cattle treated once at turnout with eprinomectin extended-release injection

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated against infections with third-stage larvae or eggs of gastrointestinal and pulmonary nematodes in cattle under 120-day natural challenge conditions in a series of five studies conducted in the USA (three studies) and in Europe (two studies). For each study, 30 nematode-free (four studies) or 30 cattle harboring naturally acquired nematode infections (one study) were included. The cattle were of various breeds or crosses, weighed 107.5–273 kg prior to treatment and aged approximately 4–11 months. For each study, animals were blocked based on pre-treatment bodyweight and then randomly allocated to treatment: ERI vehicle (control) at 1 mL/50 kg bodyweight or Eprinomectin 5% (w/v) ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg) for a total of 15 and 15 animals in each group. Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. In each study, all animals grazed one naturally contaminated pasture for 120 days. At regular intervals during the studies, fecal samples from all cattle were examined for nematode egg and larval counts. In four studies pairs of tracer cattle were used to monitor pasture infectivity at 28-day intervals before and/or during the grazing period. All calves were weighed before turnout onto pasture and at regular intervals until housing on Day 120. For parasite recovery, all study animals were humanely euthanized 27–30 days after removal from pasture.     

The efficacy of eprinomectin extended-release injection against Hypoderma spp. (Diptera: Oestridae) in cattle

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was determined in cattle harboring naturally acquired infestations of first- or second- and third-stage larvae of Hypoderma spp. in three studies conducted according to the same protocol in the USA (two studies) and Germany (one study). Thirty cattle sourced from herds with a history of Hypoderma infestation were included in each study. Cattle were formed into replicates of three animals each on the basis of pre-treatment anti-Hypoderma antibody titers. Within replicates each animal was randomly allocated to one of the following treatments: ERI vehicle (control) at 1 mL/50 kg bodyweight, administered once on Day 0; Eprinomectin 5% ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg), administered once on Day 0 (when larvae were expected to be first instars); or Eprinomectin 5% ERI at 1 mL/50 kg bodyweight (1.0 mg eprinomectin/kg), administered once when larvae were second or third instars (study dependent, Day 73, 119, or 140). Treatments were administered by subcutaneous injection in front of the shoulder. In all studies, emerging and/or expressed Hypoderma larvae were recovered, speciated, and counted and viability was determined. Eprinomectin LAI treatment was 100% (p < 0.05) efficacious against first- and second- or third-stage larvae of Hypoderma bovis (two studies) and Hypoderma lineatum (one study). All animals accepted the treatment well. No adverse reaction to treatments was observed in any animal in any study.     

The efficacy of eprinomectin extended-release injection against naturally acquired nematode parasites of cattle,with special regard to inhibited fourth-stage Ostertagia larvae

The efficacy of eprinomectin in an extended-release injection (ERI) formulation in the treatment of cattle harboring naturally acquired nematode populations (including inhibited nematodes) was evaluated. Five studies were conducted under a similar protocol in the USA, the UK, and in Germany. All study animals were infected by grazing naturally contaminated pastures. The adequacy of pasture infectivity was confirmed by examining tracer calves prior to allocation and treatment of the study animals. The cattle were of various breeds or crosses, weighing 79–491 kg, and aged approximately 6–15 months. In each study, 20 animals were infected by grazing, and then removed from pasture and housed in a manner to preclude further nematode infections for 8–16 days until treatment. Animals were blocked based on descending pre-treatment body weight and randomly allocated to one of two treatments: ERI vehicle (control) at 1 mL/50 kg body weight or eprinomectin 5% (w/v) ERI at 1 mL/50 kg body weight (1.0 mg eprinomectin/kg). Treatments were administered once on Day 0 by subcutaneous injection in front of the shoulder. For parasite recovery and count, all study animals were humanely euthanized 14/15 days after treatment. Cattle treated with eprinomectin ERI had significantly (p < 0.05) fewer of the following nematodes than the controls with overall reduction of parasite counts of ≥94%: adult Dictyocaulus viviparus, Capillaria spp., Cooperia oncophora, Cooperia pectinata, Cooperia punctata, Cooperia surnabada, Haemonchus placei, Nematodirus helvetianus, Oesophagostomum radiatum, Ostertagia lyrata, Ostertagia ostertagi, Trichostrongylus axei, Trichostrongylus colubriformis, Trichuris discolor, Trichuris skrjabini, and Trichuris spp.; developing fourth-stage larvae of Ostertagia spp. and Trichostrongylus spp.; and inhibited fourth-stage larvae of Cooperia spp., Haemonchus spp., Nematodirus spp., Oesophagostomum spp., Ostertagia spp., and Trichostrongylus spp.     

The treatment of bovine sarcoptic mange (Sarcoptes scabiei var. bovis) using eprinomectin extended-release injection

The efficacy of eprinomectin in an extended-release injection (ERI) formulation was evaluated in cattle harbouring induced infestations of Sarcoptes scabiei var. bovis (sarcoptic mange) in three studies conducted in Germany (two studies) and Austria (one study). A total of 44 cattle were included in the studies, 12 in one study and 16 in each of the other two studies. Approximately eight weeks following initial induced infestation, cattle in each study were formed into replicates of two animals each on the basis of pre-treatment bodyweights. Within replicates the animals were randomly allocated to one of two treatments: ERI vehicle (control) or Eprinomectin 5% (w/v) ERI (1.0 mg eprinomectin/kg). Treatments were administered at 1 mL/50 kg bodyweight by subcutaneous injection in front of the shoulder once on day 0. The number of live mites in skin scrapings was determined prior to treatment and at weekly intervals for eight weeks after treatment. Severity of skin lesions was evaluated and scored when skin scrapings were taken. In all studies, animals were weighed before infestation and again prior to and at 56 days after treatment.     

Pharmacokinetics of an extended‐release formulation of eprinomectin in healthy adult alpacas and its use in alpacas confirmed with mange

The study objective was to determine the pharmacokinetics and clinical effects of an extended‐release 5% eprinomectin formulation (Longrange^®) following subcutaneous (s.c.) injection in healthy (n = 6) and mange‐infected (n = 4) adult alpacas. High‐performance liquid chromatography was used to analyze plasma samples obtained at regular intervals for 161 days following a single 5 mg/kg injection s.c. in healthy alpacas, and for 5 days following each dose (3 treatments, 2 months apart) in mange‐affected animals. Skin scrapings and biopsies were performed pre‐ and post‐treatment at two comparable sites in alpacas with mange. Four alpacas served as healthy controls. Eprinomectin plasma concentrations showed a biphasic peak (C_MAX‐1: 5.72 ± 3.25 ng/mL; C_MAX‐2: 6.06 ± 2.47 ng/mL) in all animals at 3.88 ± 5.16 days and 77 ± 12.52 days, respectively. Eprinomectin plasma concentrations remained above 1.27 ± 0.96 ng/mL for up to 120 days. Hematocrit (35.8 vs. 31.3%, P < 0.003) and albumin (3.5 vs. 2.8 g/dL P < 0.006) reduced significantly over 6 months in multidose animals, while fecal egg counts did not differ between groups. Self‐limiting injection site reactions occurred in 9 of 10 animals. Pre‐ and post‐treatment skin biopsies showed reduced hyperkeratosis, but increased fibrosis, with 1 of 4 alpacas remaining positive on skin scraping for mange. In conclusion, alpacas require a higher eprinomectin dose (5.0 mg/kg s.c.) than cattle, to reach comparable plasma concentrations.     

Pathogenesis of GIII.2 bovine norovirus,CV186-OH/00/US strain in gnotobiotic calves

The pathogenesis of GIII.2 bovine norovirus (BoNoV) is not well understood. Our study demonstrated persisting diarrhea and prolonged fecal shedding, but with a lack of significant intestinal lesions in gnotobiotic (Gn) calves infected with GIII.2 BoNoV, CV186-OH/00/US strain. Nine 4 to 7-day-old Angus/Jersey crossbred Gn calves were orally inoculated with 10.0–11.9 log₁₀ genomic equivalents (GE)/calf of CV186-OH (n = 7) or mock (n = 2). Calves were euthanized at post-inoculation day (PID) 1 (n = 1) when moderate to severe lethargy was observed and at PIDs 2–6 (n = 4) after lethargy had subsided. Two calves were kept longer term (until PID 30) for monitoring fecal shedding patterns by TaqMan real-time RT-PCR (qRT-PCR). Most infected calves exhibited two clinical signs: (i) acute but persisting diarrhea and (ii) acute moderate to severe lethargy. The two infected calves, followed longer-term, had prolonged fecal viral RNA shedding [peak average titer of 11.8 (±0.2) log₁₀ GE/ml] at least until PID 20. By qRT-PCR, 5 infected calves had low viral RNA titers in serum, ranging from 4.0 to 5.8 log₁₀ GE/ml, at PIDs 1–5, but not (<2.7 log₁₀ GE/ml) at PIDs 6–30. The latter observation coincided with the presence of serum IgG antibody to BoNoV at PIDs 8–30. Collectively, the GIII.2 BoNoV strain CV186-OH induced only mild enteropathogenicity, evident by the lack of significant intestinal lesions, but it led to persisting mild diarrhea and prolonged fecal virus shedding in Gn calves. The prolonged fecal shedding of GIII.2 BoNoV might partially explain how this virus is maintained as endemic infections in cattle.     

Pharmacokinetics of Eprinomectin in Plasma and Milk following Subcutaneous Administration to Lactating Dairy Cattle

Eprinomectin is only available as a topically applied anthelmintic for dairy cattle. To determine whether eprinomectin can be applied as an injectable formulation in dairy cattle, a novel injectable formulation was developed and was subcutaneously delivered to four lactating dairy cattle at a dose rate of 0.2 mg/ kg. Plasma and milk samples were collected. The concentrations of eprinomectin in all samples were determined by HPLC. The peak plasma concentration (C_max)of 44.0±24.2 ng/ml occurred 39±19.3 h after subcutaneous administration, equivalent to the C_max (43.76±18.23 ng/ml) previously reported for dairy cattle after a pour-on administration of 0.5 mg/kg eprinomectin. The area under the plasma concentration–time curve (AUC) after subcutaneous administration was 7354±1861 (ng h)/ml, higher than that obtained after pour-on delivery (5737.68±412.80 (ng h)/ml). The mean residence time (MRT) of the drug in plasma was 211±55.2 h. Eprinomectin was detected in the milk at the second sampling time. The concentration of drug in milk was parallel to that in plasma, with a milk to plasma ratio of 0.16±0.01. The highest detected concentration of eprinomectin in milk was 9.0 ng/ml, below the maximum residue limit (MRL) of eprinomectin in milk established by the Joint FAO/WHO Expert Committee on Food Additives in 2000. The amount of eprinomectin recovered in the milk during this trial was 0.39%±0.08% of the total administered dose. This study demonstrates that subcutaneous administration of eprinomectin led to higher bioavailability and a lower dose than a pour-on application, and that an injectable formulation of eprinomectin may be applied in dairy cattle with a zero withdrawal period.     

Descriptive and spatial epidemiology of bovine cysticercosis in North-Eastern Spain (Catalonia)

From March 2005 to December 2007, 284 animals from 67 cattle farms (24 dairy and 43 beef) affected by bovine cysticercosis were detected in the region of Catalonia (North-Eastern Spain). Dairy farms were almost twice more likely to be affected than beef farms (OR = 1.79, 95% CI = 1.08–2.96, p < 0.05), and infected premises have a statistically significant (p < 0.05) larger number of animals when compared to uninfected farms in Catalonia.     

The effects of CO2 gas stunning on meat quality of cattle compared with captive bolt stunning

The aim of this study is to assess the effect of CO₂ gas stunning which has not been conducted until now in comparison with captive bolt stunning on the meat quality of cattle. A total of 40 steers were slaughtered following two stunning processes: CO₂ gas stunning (n=20), exposure at 70% CO₂ gas atmosphere for 140 sec; and captive bolt stunning (CBS, n=20). The slaughtered steers were classified into Group A (620–710 kg) and Group B (720–790 kg) by their live weight. CO₂ gas stunning decreases pH value (p<0.05) but increases lightness (p<0.001) and sarcomere length (p<0.001 and p<0.01 for Group A and Group B, respectively) in all live weight groups. Drip loss was increased with CO₂ gas stunning in Group A (620–710 kg of live weight) (p<0.05), whereas WBSF was decreased with CO₂ gas stunning in Group B (720–790 kg of live weight) (p<0.001). Therefore, CO₂ gas stunning negatively affects muscle pH and water-holding capacity in steers but CO₂ gas stunning can improve the tenderness and lightness compared with captive bolt stunning in cattle.     

Molasses level in lamb high-energy diets on productive performance,blood chemistry,liver minerals and histopathology

The objective of this study was to determine the effect of increasing levels of molasses on growth performance, carcass characteristics, blood chemistry, liver minerals and histopathology of lambs. Twenty intact male pelibuey lambs with an average weight of 22.4±2.8 kg were randomly assigned to one of the four experimental diets containing 0, 60, 120 and 180 g molasses/kg feed (as fed basis) in a completely random design. Lambs were individually confined to 1.5 m² pens. The experiment had a 15-day adaptation period and a 60-day experimental period. As molasses content in the ration increased from 0 to 180 g/kg, S increased from 1.1 to 2.1 g/kg DM, whereas Cu concentration ranged from 17.3 to 18.4 mg/kg DM. All diets contained high concentrations of Fe (198–252 mg/kg DM) and Zn (85–104 mg/kg DM), and low Mo contents (1.4–1.5 mg/kg DM). Molasses level had no effect (P>0.05) on DM intake, average daily gain, gain:feed, slaughter weight, full or empty gastrointestinal tract weight, digesta-free weight, hot and chilled carcass weights, dressing percent, longissimus muscle area, marbling, back-fat thickness, yield grade or KPH fat. Most of the lamb carcasses of this study were graded with small to slight marbling. The clinical status of the lambs was evaluated through histological and blood chemistry tests, obtaining samples on days 0, 15, 30 and 60. Although most blood parameters were within normal ranges, blood urea nitrogen, creatinine and cholesterol concentrations decreased (linear; P<0.05) as molasses increased in the diet. Concentrations of the enzymes serum glutamic oxaloacetic transaminase, alkaline phosphatase and creatine phosphokinase were also reduced (linear; P<0.05). Concomitant reductions (P<0.01) in liver Zn and Mo concentrations were also noticed. Although no differences (P>0.05) were observed in liver histopathological observations between treatments, Cu-related sub-lethal hepatic damage was evident in all animals, in absence of clinical signs. Special stain showed fine grained Cu deposits within hepatocytes in three cases belonging to different treatments. It appears that lambs consuming the control diet without molasses with a low S content (0.11%) were as susceptible to a pre-hemolytic copper poisoning (Pre-HCP) as those consuming the other diets containing higher Cu concentrations.     

Does Rhipicephalus microplus tick infestation increase the risk for myiasis caused by Cochliomyia hominivorax in cattle?

The larval phase of Cochliomyia hominivorax (screwworm) is an obligate parasite of vertebrate animals, particularly mammals, and widespread in South America, where it remains one of the most important parasitic diseases of domestic animals. The skin of cattle highly infested by ticks, with cutaneous lesions, exudation of tissue fluid and blood scent seems to produce the ideal environment for fly attraction. However, an association between these parasites was never investigated. The aim of this work was to verify if there is an association between Rhipicephalus microplus tick load and the occurrence of C. hominivorax myiasis in cattle, and to quantify the risk. Sixty bovine (Bos taurus taurus, Angus breed) under field conditions were observed for 24 weeks, during which weekly tick counts and examination for the presence of myiasis were performed. There was a significant association between a high tick burden (24-week mean above 50 ticks per animal) and myiasis occurrence (P = 0.0102). The calculated relative risk (RR) for C. hominivorax myiasis occurrence in cattle with high tick burden was 3.85 (CI95% = 1.23–12.13); indicating that cattle highly parasitized by R. microplus have about four times more risk of myiasis than those with a low parasite load. As far as we aware, this is the first statistically based evidence of the relationship between R. microplus parasitic load and occurrence of myiasis by C. hominivorax. This result could be useful for the design of integrated control strategies for these parasites and to provide more information for the understanding of cattle tick parasitism in cattle production.     

Prevalence and risk factors for Coxiella burnetii (Q fever) in Dutch dairy cattle herds based on bulk tank milk testing

Despite cattle herds can harbor Coxiella burnetii, risk factors for C. burnetii presence in dairy cattle herds are largely unknown. Therefore, C. burnetii herd prevalence and risk factors for bulk tank milk (BTM) positivity were investigated. In this cross-sectional study, a questionnaire was filled out by the farmer and BTM from 301 farms was tested by ELISA for presence of C. burnetii antibodies and PCR for presence of C. burnetii DNA. Risk factors were identified by univariable and multivariable logistic regression analyses. Antibodies to C. burnetii were detected in 81.6% (CI: 77.2–85.9) and C. burnetii DNA in 18.8% (CI: 14.4–23.1) of the BTM samples. Herd size (OR = 1.1 per 10 cows), cleaning the bedding of the cubicles at most every other day (OR = 2.8) and purchase of cattle from at least two addresses (OR = 3.1) showed a significant and positive association with ELISA positivity and use of an automatic milking system a negative association (OR = 0.3). Risk factors for PCR positivity were purchase of cattle from at least two delivery addresses (OR = 3.2), presence of cows with ticks (OR = 2.0), use of an automatic milking system (OR = 0.2) and presence of goats or sheep on the farm (OR = 0.4). Biosecurity and general hygiene seem associated with introduction and spread of C. burnetii in dairy herds.     

Effects of strategic helminthosis control on age at first lambing and lambing interval of communally grazed Menz ewes in Ethiopia

A three-year longitudinal study was conducted to evaluate effects of strategic anthelmintic treatment regimes on age at first lambing (AFL), weight at first lambing (WFL) and lambing interval (LI) of 356 communally grazed ewes and 675 lambs owned by 10 smallholder farmers in the central highlands of Ethiopia. The ewes were stratified by weight and randomly allocated to three treatment groups as untreated control (TG1), twice-dosed per year (TG2) for both nematodes and trematodes in mid-January and mid-June and four-time-dosed per year (TG3) in June for nematodes, in August–September for nematodes and adult Fasciola, in November–December and January–February for immature flukes. The fixed effect of anthelmintic treatments, parity, season and year of lambing on AFL and LI was evaluated. Mean ± standard error (SE) of lambing interval was 292 ± 3 days. Both anthelmintic treatments (TG2 and TG3) shortened (P < 0.01) LI by about 23 days compared to non-treated ewes (TG1). Season and year of lambing had a significant (P < 0.001) effect on LI. Mean ± SE of AFL and WFL was 598 ± 10 days and 17.2 ± 1.37 kg, respectively. Anthelmintic treatments and parity of dam of the ewe lamb did not affect AFL (P > 0.05). Birth and lambing seasons of the ewe lamb had significant (P < 0.05) effect on AFL. On the other hand, lambing season of the ewe had significant (P < 0.05) effect on WFL. Ewe lambs born in the long rains lambed more than 50 days earlier than the ewe lambs born in short rainy and dry seasons. Lambing occurred year-round with two peaks in August–September and December–January, each 5 months after the two rainy seasons. Anthelmintic treatment at the beginning of the two rainy seasons should improve reproductive performance of Menz ewe lambs in similar agro-ecology in the central highlands of Ethiopia.     

Field trials in New Zealand confirming the efficacy of eprinomectin applied topically to cattle

The efficacy and acceptability of eprinomectin in a topical formulation against gastro-intestinal nematodes in cattle was assessed under field conditions. Seven similar commercial dairy farms in the North and South Islands of New Zealand were included in the studies, involving 247 Holstein-Friesian, Jersey or Jersey-cross cattle. Cattle were confirmed by positive faecal nematode egg counts to have natural infections of gastro-intestinal nematodes and were held in separate treatment groups. In each replicate, four animals received eprinomectin (500 microg/kg body weight) and one animal received vehicle solution, all applied topically at 1 ml/10 kg body weight. Faecal samples were collected before, and 14 days after treatment, for faecal trongylid egg counts. Animals treated with eprinomectin had significantly lower (p < 0.05) Day 14 faecal strongylid egg counts than the controls. There were no significant differences (p > 0.10) between treated and control groups for pretreatment strongylid egg counts. No formulation runoff or adverse reactions were observed. These studies showed eprinomectin to be effective against gastro-intestinal nematode infections and safe for use in dairy cattle under natural field conditions.     

Analysis of polymorphisms of cathepsin B and cystatin B impact on economically important traits in pigs raised in Poland

The cathepsins belong to an enzyme family of lysosomal proteinases, which have a wide spectrum of function in a lot of tissues and cell types. Cathepsin B is one of intracellular proteases, whose role is to carboxydipeptidyl activity. In turn, the cystatin B (CSTB) is an intracellular thiol proteinase inhibitor. In pigs, CTSB was mapped on 14 chromosome and linked to loci genes ATP2A2, ACTN2 and ACTA1, in the region where suggestive QTL for fat deposition and meat content were identified. The CSTB gene is localized on telomeric end (1/2) q46–q49 of SSC13 and on this chromosome QTLs for daily gain and birth weight were identified. Our investigation concerned analysis of effects A72C CTSB polymorphism and Asp62Asn CSTB missense mutation on carcass traits in Polish pigs population. The significant results of A72C of CTSB mutation was observed for several growth traits in Pietrain pigs. AC genotype characterized higher carcass yield and weight of ham and loin than in AA pigs (AC — 79.3%, 6.90 kg and 10.2 kg; AA — 77.8, 6.52 and 9.89, P < 0.01). The significant effect of Asp62Asn CSTB was in two traits of Polish Large White pigs: AA animals had higher daily gain and lower number days in test compared to animals with GG genotype (AA — 973 g, 162 days; GG — 882 g, 172 days) with favorable additive genetic effects of allele g173A on LSM. The selection on A allele of CSTB should lead to increasing level of fat. In turn, increasing in population, a C allele of CTSB should affect better meat content parameters in pig population. Overall, these two polymorphisms seem not to be directly association with carcass traits, but probably are linked to unknown QTLs localized on 13 and 14 chromosomes.     

Duration of activity of topical eprinomectin against experimental infections with Teladorsagia circumcincta and Trichostrongylus colubriformis in goats

The immediate as well as the persistent anthelmintic efficacies of topically applied eprinomectin were evaluated in goats against induced infections with Teladorsagia circumcincta (2800 L3) and Trichostrongylus colubriformis (6000 L3). Twenty-three culled dairy goats were allocated to the following groups: control animals (group 1), animals treated 21 days prior to nematode infection (group 2), animals treated 7 days prior to nematode infection (group 3) and animals treated 21 days after nematode infection (group 4). Eprinomectin was applied at twice the cattle dose rate (1.0 mg/kg BW). According to the groups, necropsies were undertaken 28 days after nematode infection (groups 1-3) or 14 days after the anthelmintic treatment (group 4). Worm counts were determined for abomasum and small intestine. The curative anthelmintic efficacy of eprinomectin at 1.0 mg/kg BW on existing worm burdens was 100% against T. circumcincta and T. colubriformis. Quite similar worm burdens reductions were observed when eprinomectin was administered 7 days before infection whereas they were only 52.4 and 17.8% for T. circumcincta and T. colubriformis, respectively, for an administration of the drug 21 days prior to the nematode infection.     

Efficacy of eprinomectin against <Emphasis Type="Italic">Toxocara vitulorum</Emphasis> in calves

This study was made to investigate efficacy of eprinomectin pour-on against to Toxocara vitulorum in calves. In the study, 16 calves naturally infected with T. vitulorum were divided into two groups as treatment (eight calves) and control (eight calves). Eprinomectin (0.5 mg/kg, Eprinex®, Merial) was given to treatment group calves, and eggs per gramme were determined in the faeces on the day of pre-treatment and the second, third, fourth, fifth, sixth, 14th and 28th days of post-treatment. No side effects associated with nervous, respiratory and gastrointestinal systems were observed. In conclusion, eprinomectin was determined to be 100% effective against T. vitulorum. This is the first study to evaluate the efficacy of eprinomectin against a natural T. vitulorum infection in calves.     

Quantitative real-time PCR and culture examination of Mycobacterium avium subsp. paratuberculosis at farm level

Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne's disease in ruminants and may contribute to Crohn's disease in humans. The aim of this study was to determine the occurrence and quantity of MAP in cattle feces and milk in the Iranian context. In addition, we evaluated the effect of cattle age as well as farming system as risk factors contributing to MAP load. For this, a total sample of 373 consisting of 150 cattle feces (CF), 150 individual cow's milk (ICM), as well as 73 bulk-tank milk (BTM) was collected randomly and regardless of the cattle health status. The samples were assayed using F57 quantitative real-time PCR (qPCR) and culture method. According to the results of qPCR which was found ∼10 times more sensitive than culture assay, MAP was detected in 68.66% (103/150) of the CF, 12% (18/150) of the ICM and 52.05% (38/73) of the BTM samples. In contrast to the previous reports, the quantity of MAP in the BTM (2.03–5.97 log cfu/50 ml) was statistically (p < 0.01) higher than the ICM (0.90–1.97 log cfu/50 ml). Data suggested a direct relation (p < 0.01) between the cattle age and the quantity of MAP in the CF samples, while the relation was not statistically significant (p > 0.05) for the ICM. In addition, MAP load in the BTM samples obtained from traditional farms was significantly (p < 0.01) higher than that of the industrial ones, while the differences in CF and ICM was not significant (p > 0.05).     

Evaluation of the persistent activity of moxidectin (10%) long-acting (LA) injectable formulation against Dictyocaulus viviparus, Haemonchus placei, Trichostrongylus axei and Oesophagostomum radiatum infections in cattle

Two controlled studies were conducted to evaluate the persistent efficacy of moxidectin (10%) long-acting (LA) injectable formulation against Dictyocaulus viviparus, Haemonchus placei, Trichostrongylus axei and Oesophagostomum radiatum in cattle. The moxidectin LA injectable formulation was administered as a single subcutaneous injection into the proximal third of the ear at a dose rate of 0.01 ml/kg BW to provide 1.0 mg moxidectin/kg BW. The product had persistent efficacy of >90% against D. viviparus, H. placei and Oe. radiatum for at least 150 days post-treatment and against T. axei for at least 90 days post-treatment.